AVEO Pharmaceuticals (STU:VPA1) Change In Other Working Capital : €1.25 Mil (TTM As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Change In Other Working Capital?

AVEO Pharmaceuticals's Change In Other Working Capital for the quarter that ended in Sep. 2022 was €3.09 Mil. It means AVEO Pharmaceuticals's Other Working Capital increased by €3.09 Mil from Jun. 2022 to Sep. 2022 .

AVEO Pharmaceuticals's Change In Other Working Capital for the fiscal year that ended in Dec. 2021 was €-0.19 Mil. It means AVEO Pharmaceuticals's Other Working Capital declined by €0.19 Mil from Dec. 2020 to Dec. 2021 .

AVEO Pharmaceuticals Change In Other Working Capital Historical Data

The historical data trend for AVEO Pharmaceuticals's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Change In Other Working Capital Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Other Working Capital

Get a 7-Day Free Trial

1.33

0.35

-0.95

-0.38

-0.19

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Other Working Capital	Get a 7-Day Free Trial															1.87	-3.11	-0.32	1.59	3.09

AVEO Pharmaceuticals Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.25 Mil.

AVEO Pharmaceuticals Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines